Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2427807rdf:typepubmed:Citationlld:pubmed
pubmed-article:2427807lifeskim:mentionsumls-concept:C0018801lld:lifeskim
pubmed-article:2427807lifeskim:mentionsumls-concept:C0013072lld:lifeskim
pubmed-article:2427807lifeskim:mentionsumls-concept:C0232804lld:lifeskim
pubmed-article:2427807lifeskim:mentionsumls-concept:C0006938lld:lifeskim
pubmed-article:2427807lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:2427807pubmed:issue4lld:pubmed
pubmed-article:2427807pubmed:dateCreated1986-9-29lld:pubmed
pubmed-article:2427807pubmed:abstractTextThere remains controversy over the effects of angiotensin-converting enzyme inhibitors on renal function in patients with heart failure. Accordingly, we investigated the effects of long-term captopril therapy on renal function in 14 patients with congestive heart failure in a double-blind fashion. Creatinine clearance declined (from 61 +/- 21 to 56 +/- 21 ml/min; p less than 0.01), and both serum urea and creatinine rose. Glomerular filtration rate estimated radioisotopically also fell (from 53 +/- 19 to 48 +/- 18 ml/min), although this was not statistically significant. Effective renal plasma flow estimated radioisotopically increased (from 241 +/- 72 to 287 +/- 100 ml/min; p less than 0.05). Thus, filtration fraction--the ratio of glomerular filtration rate to effective renal plasma flow--fell. Because blood pressure also fell, the rise in renal plasma flow indicates a fall in calculated renal vascular resistance. Whole body sodium and chlorine, measured by total body in vivo neutron activation analysis, were unchanged, indicating no long-term natriuresis, despite evidence of clinical improvement. While converting enzyme inhibition causes symptomatic improvement in cardiac failure, there is a concomitant loss of compensatory direct effects of angiotensin II within the kidney, and hence usually some decline in renal function.lld:pubmed
pubmed-article:2427807pubmed:languageenglld:pubmed
pubmed-article:2427807pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2427807pubmed:citationSubsetIMlld:pubmed
pubmed-article:2427807pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2427807pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2427807pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2427807pubmed:statusMEDLINElld:pubmed
pubmed-article:2427807pubmed:issn0160-2446lld:pubmed
pubmed-article:2427807pubmed:authorpubmed-author:MortonJ JJJlld:pubmed
pubmed-article:2427807pubmed:authorpubmed-author:RobertsonJ...lld:pubmed
pubmed-article:2427807pubmed:authorpubmed-author:RobertsonIIlld:pubmed
pubmed-article:2427807pubmed:authorpubmed-author:BallS GSGlld:pubmed
pubmed-article:2427807pubmed:authorpubmed-author:DargieH JHJlld:pubmed
pubmed-article:2427807pubmed:authorpubmed-author:EastB WBWlld:pubmed
pubmed-article:2427807pubmed:authorpubmed-author:ClelandJ GJGlld:pubmed
pubmed-article:2427807pubmed:authorpubmed-author:GillenGGlld:pubmed
pubmed-article:2427807pubmed:issnTypePrintlld:pubmed
pubmed-article:2427807pubmed:volume8lld:pubmed
pubmed-article:2427807pubmed:ownerNLMlld:pubmed
pubmed-article:2427807pubmed:authorsCompleteYlld:pubmed
pubmed-article:2427807pubmed:pagination700-6lld:pubmed
pubmed-article:2427807pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:2427807pubmed:meshHeadingpubmed-meshheading:2427807-...lld:pubmed
pubmed-article:2427807pubmed:meshHeadingpubmed-meshheading:2427807-...lld:pubmed
pubmed-article:2427807pubmed:meshHeadingpubmed-meshheading:2427807-...lld:pubmed
pubmed-article:2427807pubmed:meshHeadingpubmed-meshheading:2427807-...lld:pubmed
pubmed-article:2427807pubmed:meshHeadingpubmed-meshheading:2427807-...lld:pubmed
pubmed-article:2427807pubmed:meshHeadingpubmed-meshheading:2427807-...lld:pubmed
pubmed-article:2427807pubmed:meshHeadingpubmed-meshheading:2427807-...lld:pubmed
pubmed-article:2427807pubmed:meshHeadingpubmed-meshheading:2427807-...lld:pubmed
pubmed-article:2427807pubmed:meshHeadingpubmed-meshheading:2427807-...lld:pubmed
pubmed-article:2427807pubmed:meshHeadingpubmed-meshheading:2427807-...lld:pubmed
pubmed-article:2427807pubmed:meshHeadingpubmed-meshheading:2427807-...lld:pubmed
pubmed-article:2427807pubmed:meshHeadingpubmed-meshheading:2427807-...lld:pubmed
pubmed-article:2427807pubmed:meshHeadingpubmed-meshheading:2427807-...lld:pubmed
pubmed-article:2427807pubmed:articleTitleCaptopril in heart failure: a double-blind study of the effects on renal function.lld:pubmed
pubmed-article:2427807pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2427807pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:2427807pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:2427807pubmed:publicationTypeControlled Clinical Triallld:pubmed
pubmed-article:2427807pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed